Künig G, Leenders K L, Antonini A, Vontobel P, Weindl A, Meinck H M
PET Program, Paul Scherrer Institute, Villigen, Germany.
Ann Neurol. 1998 Nov;44(5):758-62. doi: 10.1002/ana.410440509.
We have studied dopamine D2 receptor binding by [11C]raclopride positron emission tomography in 14 patients with dopa-responsive dystonia (DRD). Data were compared with 16 levodopa-treated patients with Parkinson's disease (PD) and 26 healthy controls. The results revealed an elevated [11C]raclopride binding index in the putamen and caudate nucleus of DRD patients compared with controls as well as a significant elevation in the caudate nucleus compared with PD patients. The increase of [11C]raclopride binding may be interpreted either as reduced tracer displacement by endogenous dopamine, or as an alteration of the receptor features due to chronic dopamine deficiency. The difference in [11C]raclopride binding in DRD and PD patients in the caudate nucleus suggests that this structure may be of pathophysiological relevance in the presentation of the clinical features of both diseases.
我们通过[11C]雷氯必利正电子发射断层扫描研究了14例多巴反应性肌张力障碍（DRD）患者的多巴胺D2受体结合情况。将数据与16例接受左旋多巴治疗的帕金森病（PD）患者和26名健康对照者进行了比较。结果显示，与对照组相比，DRD患者壳核和尾状核的[11C]雷氯必利结合指数升高，与PD患者相比，尾状核也有显著升高。[11C]雷氯必利结合的增加可以解释为内源性多巴胺对示踪剂的置换减少，或者是由于慢性多巴胺缺乏导致的受体特征改变。DRD和PD患者尾状核中[11C]雷氯必利结合的差异表明，该结构可能在两种疾病临床特征的表现中具有病理生理学意义。
